Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Wall Street Zen

Grifols (NASDAQ:GRFS) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other brokerages have also issued reports on GRFS. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $10.00.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $7.31 on Friday. The company’s fifty day moving average price is $7.75 and its 200 day moving average price is $7.82. Grifols has a 12 month low of $6.96 and a 12 month high of $10.23. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. The firm has a market capitalization of $4.98 billion, a P/E ratio of 38.47, a P/E/G ratio of 0.27 and a beta of 0.67.

Institutional Trading of Grifols

A number of hedge funds have recently added to or reduced their stakes in the stock. Flat Footed LLC increased its stake in Grifols by 26.5% in the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after buying an additional 287,867 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Grifols by 42.0% in the 1st quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after acquiring an additional 104,418 shares during the period. Norges Bank acquired a new stake in shares of Grifols in the 4th quarter worth $18,139,000. Royal Bank of Canada boosted its holdings in shares of Grifols by 15.4% in the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock valued at $6,301,000 after acquiring an additional 104,850 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Grifols by 13.8% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock valued at $4,193,000 after acquiring an additional 72,037 shares in the last quarter.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.